Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemborexant - Eisai

Next Previous
Search
Drug Profile

Lemborexant - Eisai

Alternative Names: DAYVIGO; DAYVIGOTM; E-2006; LEM - Eisai

Latest Information Update: 26 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Class Amides; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Phase II Circadian rhythm sleep disorders
  • No development reported Chronic obstructive pulmonary disease; Sleep apnoea syndrome

Most Recent Events

  • 24 May 2024 Eisai completes a phase II trial for Insomnia in South Korea (PO, Tablet) (NCT05594589)
  • 01 Feb 2024 Eisai plans to launch lemborexant for Insomnia in South Africa (PO) in June 2024
  • 31 Jan 2024 Preregistration for Insomnia (In the elderly, In adults) in China (PO) (Eisai Pipeline, February 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top